Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda
Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda
复制标题
DOI：
10.1111/tmi.12717
复制
发表时间：
2016-07-01
影响因子：
3.3
通讯作者：
Nsanzimana, Sabin
中科院分区：
文献类型：
--
作者：
Ndahimana, Jean d'Amour;Riedel, David J.;Nsanzimana, Sabin
ObjectiveTo evaluate HIV drug resistance (HIVDR) and determinants of virological failure in a large cohort of patients receiving first-line tenofovir-based antiretroviral therapy (ART) regimens.MethodsA nationwide retrospective cohort from 42 health facilities was assessed for virological failure and development of HIVDR mutations. Data were collected at ART initiation and at 12 months of ART on patients with available HIV-1 viral load (VL) and ART adherence measurements. HIV resistance genotyping was performed on patients with VL 1000 copies/ml. Multiple logistic regression was used to determine factors associated with treatment failure.ResultsOf 828 patients, 66% were women, and the median age was 37 years. Of the 597 patients from whom blood samples were collected, 86.9% were virologically suppressed, while 11.9% were not. Virological failure was strongly associated with age
